Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Royalty Pharma plc RPRX

Healthcare Biotechnology
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including... see more

Recent & Breaking News (NDAQ:RPRX)

Royalty Pharma to Present at Upcoming Investor Conferences

GlobeNewswire November 27, 2024

Royalty Pharma Announces Inaugural Prize for Impact in Healthcare

GlobeNewswire November 14, 2024

Royalty Pharma to Acquire Royalty Interest in Geron's RYTELO for $125 Million

GlobeNewswire November 7, 2024

Royalty Pharma Reports Third Quarter 2024 Results

GlobeNewswire November 6, 2024

Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo

GlobeNewswire November 4, 2024

Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo(TM)

PR Newswire November 4, 2024

Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024

GlobeNewswire October 16, 2024

Royalty Pharma Declares Fourth Quarter 2024 Dividend

GlobeNewswire October 11, 2024

Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement

GlobeNewswire September 3, 2024

Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement

GlobeNewswire September 3, 2024

Royalty Pharma to Present at Morgan Stanley's 22nd Annual Global Healthcare Conference

GlobeNewswire August 28, 2024

Royalty Pharma Reports Second Quarter 2024 Results

GlobeNewswire August 8, 2024

Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital

GlobeNewswire July 24, 2024

Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024

GlobeNewswire July 19, 2024

Royalty Pharma Declares Third Quarter 2024 Dividend

GlobeNewswire July 17, 2024

Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

GlobeNewswire June 4, 2024

Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes

GlobeNewswire June 3, 2024

Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million

GlobeNewswire May 28, 2024

Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline

GlobeNewswire May 22, 2024

Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline

GlobeNewswire May 22, 2024